Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 13/20 | 0.35 |
| ▸ | CNR1 | P21554 | 10/20 | 0.35 |
| ▸ | PDE4A | P27815 | 2/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20313506 | 1.00 | PLA2G2A (0.36) | PLA2G2ACNR2CNR1PDE4APDE4D | |
| SCHEMBL19855382 | 0.90 | PARP15 (0.37) | PDE4APDE4DPDE3BPDE3APARP15 | |
| SCHEMBL20313486 | 0.85 | CYP2C9 (0.36) | CNR2CNR1MEN1HTTKMT2A | |
| SCHEMBL19854034 | 0.83 | CNR1 (0.33) | CNR2CNR1MEN1HTTKMT2A | |
| SCHEMBL19854033 | 0.81 | PKM (0.31) | MEN1HTTKMT2A | |
| SCHEMBL20313629 | 0.80 | CYP2C9 (0.32) | MEN1HTTKMT2A | |
| SCHEMBL19855419 | 0.80 | MRGPRX4 (0.40) | CNR2CNR1 | |
| SCHEMBL19854418 | 0.80 | CYP2C9 (0.40) | MEN1KMT2A | |
| SCHEMBL19854697 | 0.80 | THRB (0.36) | MEN1KMT2A | |
| SCHEMBL20313503 | 0.80 | LSS (0.31) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214615-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT | JNC CORPORATION (JP) | 2021-07-15 | — | — | US | disclosed |
| EP-3351525-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC Corporation (JP) | 2018-07-25 | — | — | EP | disclosed |
| US-20180179443-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-06-28 | — | — | US | disclosed |
| US-20180179443-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-06-28 | — | — | US | disclosed |
| WO-2018025974-A1 | LIQUID-CRYSTAL DISPLAY ELEMENT AND DISPLAY DEVICE | JNC株式会社 | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179443-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | C1S, CCND1, C5 | PLA2G2A 1676/4885CNR2 668/4885CNR1 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.